Prevalent Pancreatic Cancer Cases will Increase to 59,675 by 2022

Friday 9 August 2013, Amsterdam

This new report forecasts that the US and Germany will have the highest number of incident cases of pancreatic cancer in 2022, with 53,610 and 27,629 cases, respectively. This reports epidemiologists also expect that the number of prevalent cases of pancreatic cancer in the 6 major markets covered (US, France, Germany, Italy, Spain, and UK) will increase during the forecast period (2012-2022) to a total of 59,675 cases. The stage at diagnosis for pancreatic cancer is correlated with the availability of screening tests and the ability to identify early symptoms. Due to the inability to identify early indications of the illness, pancreatic cancer cases are most commonly diagnosed in Stage IV. Greater research in prevention and early diagnostic testing can help reduce the incidence of the disease. Through early detection, it may be possible to stop the spread of the cancer to other organs and decrease the overall mortality.

The "EpiCast Report: Pancreatic Cancer - Epidemiology Forecast to 2022", provides an overview of the risk factors and global trends of pancreatic cancer in the six major markets (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of the incident cases of pancreatic cancer segmented by sex, age (in five-year increments beginning at 15 years and ending at ages 85 years and older), stage at diagnosis, the proportion of incident cases that undergo resection, locally-advanced unresectable cases, metastatic cases, and biomarker mutation type (KRAS and HER2) in these markets, along with the prevalent cases.